AbbVie posts Q3 2026 results, raises FY‑2026 adjusted EPS guidance and dividend
+1 new source since this summary was written
AbbVie reported third‑quarter 2026 revenue of $17.404 billion, up 10.3 % year over year. GAAP EPS was $2.37 and adjusted EPS was $3.82, both more than double the prior year. The company lifted its full‑year adjusted diluted EPS guidance to $13.95‑$13.99 per share and announced a 5.2 % increase to its quarterly dividend for 2027. The results were driven by strong sales of Skyrizi and Rinvoq, while Humira sales fell.
Why it matters
The higher guidance signals stronger earnings potential for FY‑2026, which may support a higher valuation for ABBV (the company expects adjusted EPS of $13.95‑$13.99). The dividend increase improves the yield for income‑focused investors.
Key facts
- 1Third‑quarter net revenues were $17.404 billion, an increase of 10.3 % on a reported basis. prnewswire.com
- 2GAAP diluted EPS for the quarter was $2.37, an increase of over 100 %. prnewswire.com
- 3Adjusted diluted EPS for the quarter was $3.82, an increase of over 100 %. prnewswire.com
- 4Global Skyrizi net revenues were $5.776 billion, up 22.7 % on a reported basis. prnewswire.com
- 5Global Rinvoq net revenues were $2.706 billion, up 23.9 % on a reported basis. prnewswire.com
- 6The company raised its 2026 adjusted diluted EPS guidance range to $13.95‑$13.99 per share. prnewswire.com
Summary written by AlphAI AI Desk from 20 of 38 sources. Not investment advice. Figures are as stated by the linked sources.